Syed Haider

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Supplementary Figure 2 from LOX Inhibition Disrupts a Collagen–Integrin–MYC Axis to Suppress Progression of Invasive Lobular Carcinoma

  2026-06-17

• Supplementary Figure 3 from LOX Inhibition Disrupts a Collagen–Integrin–MYC Axis to Suppress Progression of Invasive Lobular Carcinoma

  2026-06-17

• Data from LOX Inhibition Disrupts a Collagen–Integrin–MYC Axis to Suppress Progression of Invasive Lobular Carcinoma

  2026-06-17

• Supplementary Figure 6 from LOX Inhibition Disrupts a Collagen–Integrin–MYC Axis to Suppress Progression of Invasive Lobular Carcinoma

  2026-06-17

• Supplementary Figure 4 from LOX Inhibition Disrupts a Collagen–Integrin–MYC Axis to Suppress Progression of Invasive Lobular Carcinoma

  2026-06-17

• Supplementary Figure 5 from LOX Inhibition Disrupts a Collagen–Integrin–MYC Axis to Suppress Progression of Invasive Lobular Carcinoma

  2026-06-17

• Supplementary Figure 1 from LOX Inhibition Disrupts a Collagen–Integrin–MYC Axis to Suppress Progression of Invasive Lobular Carcinoma

  2026-06-17

• COBLE

  Zenodo (CERN European Organization for Nuclear Research) · 2026-06-13

• Refining the Multivariable Predictive‐Prognostic <scp>PREDICTR</scp> ‐ <scp>OPC</scp> Model for Survival in Surgical Escalation for Oropharyngeal Squamous Cell Carcinoma

  The Laryngoscope · 2026-05-12

• A Randomized, Phase II Clinical Trial of FLT-PET and FDG-PET for Early Response Assessment of Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer

  Clinical Cancer Research · 2026-04-28

• Disparities in Limb-Saving Surgery Persist Among Black Patients With Peripheral Artery Disease

  Cureus · 2026-03-21

• Supplementary Table S1 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

  2025-11-25

• Supplementary Figure S4 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

  2025-11-25

• Supplementary Figure S1 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

  2025-11-25

• Supplementary Figure S5 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

  2025-11-25

• Supplementary Figure S3 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

  2025-11-25

• Supplementary Figure S2 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

  2025-11-25

• Supplementary Table S3 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

  2025-11-25

• Supplementary Table S4 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

  2025-11-25

• Supplementary Table S2 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

  2025-11-25